Axcynsis Therapeutics is a multi-platform antibody-drug conjugate (ADC) development company focused on creating next-generation ADC therapies incorporating a proprietary payload, AxcynDOT, designed to overcome drug resistance and address significant unmet medical needs in oncology. Headquartered in Singapore, Axcynsis leverages advanced ADC engineering and translational science to build a differentiated pipeline targeting solid tumors. The company’s lead asset has received Investigational New Drug (IND) approval from the U.S. FDA with Fast Track designation, and is expected to enter Phase 1 clinical trials in 2025. Axcynsis is committed to delivering transformative cancer therapies that improve patient outcomes globally.